| Literature DB >> 16734512 |
Myke R Green1, Sajeel Chowdhary, Kristina M Lombardi, Lisa M Chalmers, Marc Chamberlain.
Abstract
Primary CNS non-Hodgkin lymphoma (PCNSL) has been shown to be increasing in incidence. This appears to be a consequence of the increasing population of those older than 65 years of age in whom PCNSL occurs most often. PCNSL often has a favorable response to treatment and aggressive management may result in extended survival and, in a proportion of patients less than 65 years of age, cure. The majority of neuro-oncologist's advocate utilizing high-dose methotrexate (HD-MTX) as a platform for the chemotherapy treatment of these neoplasms. In this review, the literature regarding HDHMTX as a treatment for PCNSL is summarized as are the pharmacological principles of HD-MTX.Entities:
Mesh：
Substances：
Year: 2006 PMID： 16734512 DOI： 10.1586/14737175.6.5.635
Source DB: PubMed Journal: Expert Rev Neurother ISSN： 1473-7175 Impact factor: 4.618